Please login to the form below

Not currently logged in
Email:
Password:

MSD invests in FKD Therapies

MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker

MSD (known as Merck in the US and Canada) has taken an equity stake in the Finland based company, FKD Therapies. FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark Therapeutics.

This investment by MSD constitutes part of a deal that will see FKD Therapies develop MSD's gene therapy portfolio, which includes a possible treatment for bladder cancer.

The possible bladder treatment that FKD Therapies will be developing contains an adenovirus, which is designed to carry an interferon gene into the bladder wall cells. Here, it expresses a protein within the bladder, possibly increasing its ability to penetrate tumour cells.

MSD's gene therapy programmes for glaucoma surgery failure and the treatment of solid tumours were also available to develop.

20th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics